Breast cancer:
Indications for: Paclitaxel
Adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. Breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
Adult Dosage:
See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. Breast cancer (node-positive): 175mg/m2 IV over 3 hours every 3 weeks for 4 courses administered sequentially to doxorubicin-containing combination chemotherapy. Breast cancer (after failure of initial chemotherapy for metastatic disease or relapse): 175mg/m2 IV over 3 hours every 3 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 or platelets <100,000cells/mm3.
Children Dosage:
Not established.
Paclitaxel Contraindications:
Baseline neutrophil count <1,500cells/mm3.
Boxed Warning:
Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.
Paclitaxel Warnings/Precautions:
Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Paclitaxel Classification:
Antimicrotubule agent.
Paclitaxel Interactions:
May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.
Adverse Reactions:
Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.
Note:
Formerly known under the brand name Taxol.
How Supplied:
Contact supplier
Gynecologic Cancers:
Kaposi's sarcoma:
Indications for: Paclitaxel
Second-line treatment of AIDS-related Kaposi's sarcoma.
Adult Dosage:
See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. 135mg/m2 IV over 3 hours every 3 weeks; or 100mg/m2 IV over 3 hours every 2 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,000cells/mm3 or platelets <100,000cells/mm3.
Children Dosage:
Not established.
Paclitaxel Contraindications:
Baseline neutrophil count <1,000cells/mm3.
Boxed Warning:
Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.
Paclitaxel Warnings/Precautions:
Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Paclitaxel Classification:
Antimicrotubule agent.
Paclitaxel Interactions:
May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.
Adverse Reactions:
Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.
Note:
Formerly known under the brand name Taxol.
How Supplied:
Contact supplier
Respiratory and thoracic cancers:
Indications for: Paclitaxel
First-line treatment of non-small cell lung cancer in combination with cisplatin in patients who are not candidates for potentially curative surgery and/or radiation therapy.
Adult Dosage:
See full labeling. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. 135mg/m2 IV over 24 hours + cisplatin every 3 weeks. Hepatic impairment or neutropenia: see full labeling for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 or platelets <100,000cells/mm3.
Children Dosage:
Not established.
Paclitaxel Contraindications:
Baseline neutrophil count <1,500cells/mm3.
Boxed Warning:
Should be administered under the supervision of an experienced physician. Anaphylaxis and severe hypersensitivity reactions. Bone marrow suppression.
Paclitaxel Warnings/Precautions:
Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Paclitaxel Classification:
Antimicrotubule agent.
Paclitaxel Interactions:
May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates, inducers and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin.
Adverse Reactions:
Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes.
Note:
Formerly known under the brand name Taxol.
How Supplied:
Contact supplier
